Latest News and Press Releases
Want to stay updated on the latest news?
-
Press Release Vifor Pharma to acquire Sanifit to further strengthen late-stage pipeline in nephrology Vifor Pharma to acquire Sanifit, a clinical-stage cardio-renal biopharmaceutical company focused...
-
Press Release Vifor Pharma to acquire Sanifit to further strengthen late-stage pipeline in nephrology Vifor Pharma to acquire Sanifit, a clinical-stage cardio-renal biopharmaceutical company...
-
Sanifit Granted Orphan Drug Designation by the FDA for SNF472 for the Treatment of Peripheral Arterial Disease in Patients with End-stage Kidney Disease Palma, Spain and San Diego, USA, February 10,...
-
Sanifit Appoints Adam Levy as Chief Financial Officer Palma, Spain and San Diego, USA, 20 August 2020 – Sanifit, a clinical-stage biopharmaceutical company focused on developing treatments for...
-
Sanifit to start new clinical development program of SNF472 in End Stage Kidney Disease patients with Peripheral Artery Disease FDA has agreed to key aspects of the clinical program, including...
-
First patient dosed in pivotal phase 3 trial of SNF472 in calciphylaxis First patient dosed in phase 3 trial of SNF472 for the treatment of calcific uremic arteriolopathy (CUA) or calciphylaxis ...
-
Positive data from Sanifit’s Phase 2b CaLIPSO trial of SNF472 published in Circulation SNF472 significantly reduced progression of cardiovascular calcification in patients with end stage kidney...
-
Positive data from Sanifit’s Phase 2b CaLIPSO trial of SNF472 published in Circulation SNF472 significantly reduced progression of cardiovascular calcification in patients with end stage kidney...
-
Sanifit announces that the Phase 2b CaLIPSO trial of SNF472 met its primary endpoint in slowing the progression of cardiovascular calcification in patients on hemodialysis Top line data to be...
-
Sanifit named as one of 2019’s “Fierce 15” biotechnology companies by FierceBiotech Palma, Spain and San Diego, USA, 23 September 2019 – Sanifit, a clinical-stage biopharmaceutical company focused on...